Credit Suisse analyst Scott Deuschle maintains BWX Technologies (NYSE:BWXT) with a Outperform and raises the price target from $65 to $67.
Why Is HIV Drug Giant Gilead Stock Falling Monday?
Gilead's Phase 3 EVOKE-01 study on Trodelvy in metastatic non-small cell lung cancer didn't meet overall survival endpoint. Despite numerical OS improvement, further exploration is planned.
